title: Randomized, double-blind, placebo-controlled, clinic-initiated, Canadian multicenter trial of topical edoxudine 3.0% cream in the treatment of recurrent genital herpes. Canadian Cooperative Study Group.
abstract: Treatment for recurrent genital herpes using edoxudine 3% cream for 5 days was evaluated in 200 patients in a randomized, multicenter, double-blind, placebo-controlled, clinic-initiated trial. Lesion tenderness was predictive of and more sensitive and longer-lasting than the symptom of pain. Among patients receiving placebo, times to crusting (P = .043), cessation of investigator-observed signs (P = .005), lesion-associated signs (P = .02), and groin signs (P = .05) were longer in women. Edoxudine reduced viral shedding in men (mean 2.7 vs. 3.4 days, P = .009) and women (2.0 days vs. 3.5 days, P = .0001). Loss of investigator-observed signs (4.4 vs. 6.2 days, P = .002), investigator-observed lesion tenderness (P = .01), lesion signs (P = .02), groin adenopathy (P = .01), and tenderness (P = .01) occurred earlier in women taking edoxudine. Edoxudine was well-tolerated and reduced several signs of herpes in women. Its clinical role in recurrent genital herpes remains to be fully determined.
authors.affiliation: Faculty of Medicine, University of British Columbia, Vancouver, Canada.
authors.forename: S L
authors.initials: SL
authors.lastname: Sacks
authors.forename: L D
authors.initials: LD
authors.lastname: Tyrrell
authors.forename: D
authors.initials: D
authors.lastname: Lawee
authors.forename: W
authors.initials: W
authors.lastname: Schlech
authors.forename: M J
authors.initials: MJ
authors.lastname: Gill
authors.forename: F Y
authors.initials: FY
authors.lastname: Aoki
authors.forename: A Y
authors.initials: AY
authors.lastname: Martel
authors.forename: J
authors.initials: J
authors.lastname: Singer
mesh_terms: D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002170:Canada; D003857:Deoxyuridine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004311:Double-Blind Method; D005260:Female; D006558:Herpes Genitalis / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D012008:Recurrence
chemical_list: D000998:Antiviral Agents; C022811:edoxudin; D003857:Deoxyuridine